LARIMAR THERAPEUTICS INC (LRMR) Stock Overview
USA - NASDAQ:LRMR - US5171251003 - Common Stock
LRMR Key Statistics, Chart & Performance
The current stock price of LRMR is 5.1 USD. In the past month the price increased by 31.78%. In the past year, price decreased by -22.37%.
LRMR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.77 | 388.63B | ||
| AMGN | AMGEN INC | 12.8 | 150.32B | ||
| GILD | GILEAD SCIENCES INC | 14.69 | 141.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.23 | 96.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.64 | 61.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.08B | ||
| ARGX | ARGENX SE - ADR | 78.72 | 44.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.77 | 39.21B | ||
| INSM | INSMED INC | N/A | 29.80B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 22.50B | ||
| BIIB | BIOGEN INC | 8.6 | 20.18B |
Related stock screener links
About LRMR
Company Profile
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Company Info
LARIMAR THERAPEUTICS INC
Three Bala Plaza East. Suite 506
Bala Cynwyd PENNSYLVANIA 19004 US
CEO: Carole Ben-Maimon
Employees: 65
Phone: 18445119056
LARIMAR THERAPEUTICS INC / LRMR FAQ
What is the stock price of LARIMAR THERAPEUTICS INC today?
The current stock price of LRMR is 5.1 USD. The price increased by 14.86% in the last trading session.
What is the ticker symbol for LARIMAR THERAPEUTICS INC stock?
The exchange symbol of LARIMAR THERAPEUTICS INC is LRMR and it is listed on the Nasdaq exchange.
On which exchange is LRMR stock listed?
LRMR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LARIMAR THERAPEUTICS INC stock?
18 analysts have analysed LRMR and the average price target is 20.03 USD. This implies a price increase of 292.73% is expected in the next year compared to the current price of 5.1. Check the LARIMAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LARIMAR THERAPEUTICS INC worth?
LARIMAR THERAPEUTICS INC (LRMR) has a market capitalization of 436.51M USD. This makes LRMR a Small Cap stock.
How many employees does LARIMAR THERAPEUTICS INC have?
LARIMAR THERAPEUTICS INC (LRMR) currently has 65 employees.
What are the support and resistance levels for LARIMAR THERAPEUTICS INC (LRMR) stock?
LARIMAR THERAPEUTICS INC (LRMR) has a support level at 4.08. Check the full technical report for a detailed analysis of LRMR support and resistance levels.
Should I buy LARIMAR THERAPEUTICS INC (LRMR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LRMR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LRMR, evaluating the profitability, health, valuation and growth aspects
- LARIMAR THERAPEUTICS INC (LRMR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LARIMAR THERAPEUTICS INC (LRMR) Sales and EPS estimates to see what analysts future expectations are.
- LARIMAR THERAPEUTICS INC (LRMR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LARIMAR THERAPEUTICS INC (LRMR) Insider and Institutional Ownership to learn about the owners and their transactions.
- LARIMAR THERAPEUTICS INC (LRMR) Stock Chart to make your own analysis
- LARIMAR THERAPEUTICS INC (LRMR) Latest news and press-releases to stay up to date.
Does LARIMAR THERAPEUTICS INC (LRMR) stock pay dividends?
LRMR does not pay a dividend.
When does LARIMAR THERAPEUTICS INC (LRMR) report earnings?
LARIMAR THERAPEUTICS INC (LRMR) will report earnings on 2025-10-28, before the market open.
What is the Price/Earnings (PE) ratio of LARIMAR THERAPEUTICS INC (LRMR)?
LARIMAR THERAPEUTICS INC (LRMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.56).
What is the Short Interest ratio of LARIMAR THERAPEUTICS INC (LRMR) stock?
The outstanding short interest for LARIMAR THERAPEUTICS INC (LRMR) is 7.56% of its float. Check the ownership tab for more information on the LRMR short interest.
LRMR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LRMR. When comparing the yearly performance of all stocks, LRMR is one of the better performing stocks in the market, outperforming 82.45% of all stocks.
LRMR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LRMR. While LRMR has a great health rating, there are worries on its profitability.
LRMR Financial Highlights
Over the last trailing twelve months LRMR reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS decreased by -39.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.53% | ||
| ROE | -83.26% | ||
| Debt/Equity | 0 |
LRMR Forecast & Estimates
18 analysts have analysed LRMR and the average price target is 20.03 USD. This implies a price increase of 292.73% is expected in the next year compared to the current price of 5.1.